HGH Fragment 176-191
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
HGH Fragment 176-191 is the bare lipolytic fragment of human growth hormone — the same residue region AOD-9604 is built from, but without the disulfide-bond / tyrosine modification that stabilizes AOD. Per the 0035 pass: “Same molecule body as AOD-9604 (without disulfide bond).” thepeptidelist.com files it under weight-loss.
Both compounds are part of the same fat-loss-peptide story: HGH itself has a fat-metabolizing portion and a growth-promoting portion, and both AOD-9604 and this bare fragment were isolated to try to capture the fat-burning slice without the rest of the hormone’s effects. The difference between the two is stabilization — and, critically, evidence depth.
What does it do in my body?
Per thepeptidelist.com: an isolated lipolytic region of HGH that may stimulate fat breakdown without affecting blood sugar or promoting cellular growth.
Mechanistically it’s marketed identically to AOD-9604 — the fat-burning slice of growth hormone, GH effects stripped out. The difference is stabilization and, critically, evidence depth.
How can it help me?
- Where the science stands: Thinnest in the metabolic-peptide cluster — 1 study cited, 0 human trials, and that one study isn’t about fat loss
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No specific adverse-event signal is documented for this compound in the source material. Because it shares AOD-9604’s mechanism (fat-loss region of HGH stripped of growth and blood-sugar effects), it’s assumed by analogy to carry a similarly benign profile — but that assumption has no independent human safety data behind it, since the only formal study on record is an unrelated in-vitro cancer-cell paper. Treat any safety claim about this specific compound as inferred, not established.
Regulatory status: research_only — not approved for human use, not eligible for compounding (per thepeptidelist.com). OHM grade: D / provisional (kept provisional, encyclopedia-only).
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
No validated protocol exists. The community treats it interchangeably with AOD-9604 (similar mcg-range subcutaneous, fasted-AM convention), but there is no human dose-finding study and no captured cheat-sheet row for this exact compound.
What should I avoid combining — and what's synergistic?
HGH Fragment 176-191 doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
The bare, unstabilized version of the same growth-hormone fragment behind AOD-9604 — same fat-burning theory, thinner evidence, and the thinnest formal data trail in the metabolic-peptide space.
| Class | Bare C-terminal fragment of human growth hormone (amino acids 176-191), same residue region as AOD-9604 but without the disulfide-bond / tyrosine stabilization |
| Mechanism (one line) | Claimed to stimulate fat breakdown from the same lipolytic HGH region, without affecting blood sugar or promoting cellular growth |
| Evidence base | Thinnest in the metabolic-peptide cluster — 1 study cited, 0 human trials, and that one study isn’t about fat loss |
| Safety record | No specific adverse-event signal documented; inherits AOD-9604’s benign no-GH-axis profile by molecular analogy, but with no independent human safety data of its own |
| Regulatory status | research_only; not FDA-approved; not eligible for compounding |
What it is
HGH Fragment 176-191 is the bare lipolytic fragment of human growth hormone — the same residue region AOD-9604 is built from, but without the disulfide-bond / tyrosine modification that stabilizes AOD. Per the 0035 pass: “Same molecule body as AOD-9604 (without disulfide bond).” thepeptidelist.com files it under weight-loss.
Both compounds are part of the same fat-loss-peptide story: HGH itself has a fat-metabolizing portion and a growth-promoting portion, and both AOD-9604 and this bare fragment were isolated to try to capture the fat-burning slice without the rest of the hormone’s effects. The difference between the two is stabilization — and, critically, evidence depth.
How it works
Per thepeptidelist.com: an isolated lipolytic region of HGH that may stimulate fat breakdown without affecting blood sugar or promoting cellular growth.
Mechanistically it’s marketed identically to AOD-9604 — the fat-burning slice of growth hormone, GH effects stripped out. The difference is stabilization and, critically, evidence depth.
What the research shows
This is the thinnest evidence base in the metabolic-peptide cluster:
- thepeptidelist.com grades it Anecdotal — 1 study cited, 0 human trials.
- The single cited study isn’t even about fat loss: it’s an in-vitro breast-cancer paper — the fragment enhanced the cytotoxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 cells (Habibullah et al., Drug Des Devel Ther 2022, PMID 35783198). That tells us nothing about human fat loss.
- OHM grade: D / provisional — “Same negative-Ph2 lineage; no independent grounding.” It inherits AOD-9604’s failed-Phase-2 story without adding any human data of its own.
The honest read: HGH Fragment 176-191 is researcher-community interest with formal data that is thin. It rides on the same GH-fragment fat-loss premise as AOD-9604 — and that premise has a negative human Phase 2 behind it. Educational mention; no recommendation.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice.
No validated protocol exists. The community treats it interchangeably with AOD-9604 (similar mcg-range subcutaneous, fasted-AM convention), but there is no human dose-finding study and no captured cheat-sheet row for this exact compound.
Side effects & management
No specific adverse-event signal is documented for this compound in the source material. Because it shares AOD-9604’s mechanism (fat-loss region of HGH stripped of growth and blood-sugar effects), it’s assumed by analogy to carry a similarly benign profile — but that assumption has no independent human safety data behind it, since the only formal study on record is an unrelated in-vitro cancer-cell paper. Treat any safety claim about this specific compound as inferred, not established.
Regulatory status
research_only — not approved for human use, not eligible for compounding (per thepeptidelist.com). OHM grade: D / provisional (kept provisional, encyclopedia-only).
Sources
- thepeptidelist.com directory profile; primary source for mechanism, evidence tier, and regulatory status (all site-derived citations carry per KB doctrine).
- OHM tier/safety grading (D/provisional; “same negative-Ph2 lineage; no independent grounding”).
- cited: 35783198 (Habibullah et al. 2022, Drug Des Devel Ther — in-vitro breast-cancer cytotoxicity model, not a fat-loss study).
Related: AOD-9604 · Retatrutide · Tesamorelin · MOTS-c · The GLP-1 Pipeline (2026).
Sources & references
- thepeptidelist.com directory profile; primary source for mechanism, evidence tier, and regulatory status (all site-derived citations carry per KB doctrine).
- OHM tier/safety grading (D/provisional; “same negative-Ph2 lineage; no independent grounding”).
- cited: 35783198 (Habibullah et al. 2022, Drug Des Devel Ther — in-vitro breast-cancer cytotoxicity model, not a fat-loss study).
Related: AOD-9604 · Retatrutide · Tesamorelin · MOTS-c · The GLP-1 Pipeline (2026).